Newsletter Tool

Today’s Big News

Jan 3, 2025

Analysts predict M&A, IPO uptick in 2025 but don't expect 'floodgates to suddenly open'

Regeneron acquires UK biotech, adding Oxular's eye disease delivery tech to portfolio

iBio pens $29M biobucks deal with AstralBio for obesity med designed to preserve muscle mass

Investor pumps $3M into cash-strapped Cyclacel in return for CEO role

Chutes & Ladders—Vincerx acquisition leads to C-suite shake-up

Drug candidate restores myelin and leg mobility in multiple sclerosis mouse model

Featured

Analysts predict M&A, IPO uptick in 2025 but don't expect 'floodgates to suddenly open'

By Nick Paul Taylor

Will 2025 be better? After another tough year, the answer to that question will shape the prospects of innumerable drug candidates and the lives of people who work in biotech. Evaluate analysts made predictions in their 2025 preview—and anyone expecting a dramatic turnaround should look away now.

Regeneron acquires UK biotech, adding Oxular's eye disease delivery tech to portfolio

By Gabrielle Masson

Regeneron has scooped up Oxular, a retinal-disease-focused company based in the U.K., closing the deal at the very end of 2024.

iBio pens $29M biobucks deal with AstralBio for obesity med designed to preserve muscle mass

By James Waldron

iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin antibody that it hopes can induce weight loss while retaining muscle mass.

Investor pumps $3M into cash-strapped Cyclacel in return for CEO role

By James Waldron

Investor David Lazar has come to the rescue of cash-strapped Cyclacel Pharmaceuticals, pumping $3 million into the biotech as well as taking on the top role and shaking up the board.

Chutes & Ladders—Vincerx acquisition leads to C-suite shake-up

By Darren Incorvaia,Zoey Becker

After being acquired by clinical-stage ADC company Oqory, Vincerx ended 2024 with a workforce reduction and C-suite clear-out that will involve Ahmed Hamdy, M.D., stepping down as CEO, while remaining as chairman.

Drug candidate restores myelin and leg mobility in multiple sclerosis mouse model

By Darren Incorvaia

An investigational drug for multiple sclerosis from Io Therapeutics has restored leg mobility and myelin nerve coatings in mice, the biotech announced Dec. 23.

Lilly looks to 'protect its interests' by moving to join FDA lawsuit over compounded tirzepatide

By Fraiser Kansteiner

After plugging $23 billion into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking to wade into a lawsuit that could allow compounding pharmacies to continue churning out the popular diabetes and obesity drugs.

2025 forecast: How will AI, regulators and the government intersect?

By Conor Hale

This year may bring major changes in how artificial intelligence shapes the healthcare industry—and vice versa—and tempering hype for the technology with ensuring patient safety will be essential.

After delay with FDA, Novartis touts pivotal trial win for intrathecal Zolgensma in older SMA patients

By Angus Liu

More than three years after Novartis’ plan for a speedy approval for its intrathecal Zolgensma was thwarted by an FDA requirement for a phase 3 trial, the company is back with a positive readout from that study, which could give the gene therapy a much-needed boost.

Fierce podcasts